Ethical principles for the use of human cellular biotechnologies
By Paul Root Wolpe, et al.,
Nature Biotechnology
| 11. 09. 2017
Recent developments in bioengineering promise the possibility of new diagnostic and treatment strategies, novel industrial processes, and innovative approaches to thorny problems in fields such as nutrition, agriculture, and biomanufacturing. As modern genetics has matured and developed technologies of increasing power, debates over risk assessments and proper applications of the technology, and over who should have decision-making power over such issues, have become more prominent. Recently, some scientists have advocated that ethicists “step out of the way,” whereas others have called for greater ethical scrutiny, or even for moratoria on some lines of research1,2. As a community, however, we must together determine the proper application of these powerful biological tools. This paper, a consensus statement of a group of interdisciplinary delegates drawn from the top biotech-producing countries of the world, offers a set of ethical principles to contribute to the ethical conversation about human cellular biotechnological research moving forward.
In May 2015, a group of over 140 delegates from the top biotech-producing countries of the world gathered in Atlanta, Georgia, USA for a three-day conference entitled...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...